ECE2018

19 May 2018
09:00-17:15		Pre-Congress Courses and Meetings
12:00-21:30		Registration ENTRANCE HALL
15:30-17:00		Satellite Symposium
17:30-18:15		ECE 2018 Opening Ceremony AUDITORIUM
18:15-18:45		Geoffrey Harris Lecture - Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans Chair(s):AJ Van der Lely (The Netherlands) & Manuela Simoni (Italy) AUDITORIUM
18:15	GH1	Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans Christos Mantzoros (USA)
18:50-19:20		EJE Prize Lecture - A gut feeling about glucagon Chair(s):Johannes Romijn (The Netherlands) AUDITORIUM
18:50	EJE1	A gut feeling about glucagon Filip Knop (Denmark)
19:25-19:55		Plenary 1: Contraception: Past and future Chair(s):Jérôme Bertherat (France) & Manuela Simoni (Italy) AUDITORIUM
19:25	PL1	Contraception: Past and future Philippe Bouchard (France)
20:15-21:30		Welcome Reception EXHIBITION AREA
20 May 2018
07:30-20:00		Registration ENTRANCE HALL
08:00-08:45		Meet The Expert - Basic Scientist 1: Mouse models in endocrine tumors Chair(s):Maria Chiara Zatelli (Italy) ROOM 113 & 114
08:00	MTBS1	Mouse models in endocrine tumors Manuel Gahete (Spain)
08:00-08:45		Meet The Expert 1 - Using diabetes technologies to improve pateint self care Chair(s):Mercedes Rigla (Spain) ROOM 117
08:00	MTE1	Using diabetes technologies to improve pateint self care
08:00-08:45		Meet The Expert 2 - Acromegaly: Optimal management after surgery Chair(s):Jens Bolleršlev (Norway) AUDITORIUM
08:00	MTE2	Acromegaly: Optimal management after surgery Michal Kršek (Czech. Rep.)
08:00-08:45		Meet The Expert 3 - Managing delayed puberty Chair(s):Nelly Pitteloud (Switzerland) ROOM 115 & 116
08:00	MTE3	Managing delayed puberty Taneli Raivio (Helsinki, Finland)
08:00-08:45		Meet The Expert 4 - Osteoporosis in men Chair(s):Manuel Muñoz Torres (Spain) ROOM 211
08:00	MTE4	Osteoporosis in men Dirk Vanderschueren (Belgium)
08:00-08:45		Meet The Expert 5 - Medullary thyroid cancer beyond surgery Chair(s):Juan Carlos Galofre (Spain) ROOM 112
08:00	MTE5	Medullary thyroid cancer beyond surgery Ana Maia (Brazil)
09:00-09:15		Interview with the ESE president AUDITORIUM
09:15-09:45		Plenary 2 - Bone regulates the Brain Chair(s):Barbara Obermayer-Pietsch (Austria) & Camilla Schalin-Jäntti (Finland) AUDITORIUM
09:15	PL2	Bone regulates the Brain Stravroula Kousteni (USA)
09:45-10:15		Tea & Coffee EXHIBITION AREA
10:15-11:45		Symposium 1: Predicting events in autoimmune thyroid disease Chair(s):Maria Alevizaki (Greece) & Mónica Marazuela (Spain) AUDITORIUM
10:15	S1.1	The THEA score in familial thyroid dysfunction Grigoris Effraimidis (Denmark)
10:45	S1.2	IgG4 related thyroid autoimmune disease Luca Chiovato (Italy)
11:15	S1.3	New scores for the prediction of Graves' disease Milos Zarkovic (Serbia)
10:15-11:45		Symposium 2: Salt and Sweet Chair(s):Isabel Runkle de la Vega (Spain) & Chris Thompson (Ireland) ROOM 112
10:15	S2.1	Hyponatremia and mortality: moving beyond associations Ewout Hoorn (The Netherlands)
10:45	S2.2	Hereditary Diabetes insipidus Jonas Rutishauser (Switzerland)
11:15	S2.3	Sweet preference induced by FGF21 Niels Grarup (Denmark)
10:15-11:45		Symposium 3: Bile Acid and Microbiota Chair(s):Filip Knop (Denmark) & Christos Mantzoros (USA) ROOM 211
10:15	S3.1	Crosstalk between bile acids and intestinal microbiota - influence on host metabolism Hanns-Ulrich Marschall (Sweden)
10:45	S3.2	5β-reductase, bile acid synthesis, and the control of energy metabolism Laura Gathercole (Oxford)
11:15	S3.3	Bile acids and metabolic effects of bariatric surgery Glenn. Gerhard (USA)
10:15-11:45		Symposium 4: Environmental Effects on Endocrine Function Chair(s):Anna Fadieieva (Ukraine) & Vera Popovic-Brkic (Serbia) ROOM 117
10:15	S4.1	Developmental Reprogramming of the Epigenome by Endocrine Disrupting Chemicals that Increase Cancer Risk Cheryl Walker (USA)
10:45	S4.2	Iodine deficiency in pregnancy and development of offspring Malgorzata Trofimiuk-Müldner (Poland)
11:15	S4.3	Environmental contaminants and endocrine disruption: The story of obesogens Ana Sousa (Portugal)
10:15-11:45		Symposium 5: The role of sperm epigenome in fertility and inheritance Chair(s):George Mastorakos (Greece) & Ilpo Huhtaniemi (UK/Finland) ROOM 113 & 114
10:15	S5.1	The quality control of the male germline transcriptome Noora Kotaja (Finland)
10:45	S5.2	Epigenetic germline mosaicism in infertile men Jörg Gromoll (Germany)
11:15	S5.3	Mechanisms of epigenetic inheritance through sperm: lessons we have learnt from model organisms Tanya Vavouri (Greece))
10:15-11:45		Nurses MDT symposium: Immunotherapy: The Good, The Bad and Witty Chair(s):John Ayuk (UK) ROOM 111
10:15	N1.1	The Good- Overview and Indications of Immunotherapy in Oncology Rachel Powell (UK)
10:45	N1.2	The Bad - Immunotherapy-induced Endocrinopathy Niki Karavitaki (University of Birmingham, Birmingham, UK)
11:15	N1.3	The Witty - The Role of Endocrine Nurse in Managing Patients with Immunotherapy-induced Endocrinopathy Sherwin Criseno (University Hospitals Birmingham, Birmingham , United Kingdom)
10:15-11:45		Special Symposium: Bone & Vitamin D Chair(s):Martin Hewison (UK) & Gherardo Maziotti (Italy) ROOM 115 & 116
10:15	SS1.1	Free and bound vitamin D and health outcomes. Inez Schoenmakers (UK)
10:45	SS1.2	Vitamin D and Critical Care Karin Amrein (Austria)
11:15	SS1.3	Vitamin D, macrophages and atherosclerosis Carlos Bernal-Mizrachi (USA)
12:00-13:00		Oral Communication: Benign thyroid diseases Chair(s):Alicija Hubaleswska (Poland) & Robin Peeters (The Netherlands) ROOM 112
12:00	OC1.1	Familial gestational hyperthyroidism caused by Val597Ile mutant of TSH receptor gene with human chorionic gonadotropin hypersensitivity Philippe Caron (France)
12:12	OC1.2	Relationship between TSH values in the first trimester of pregnancy and obstetric and neonatal complications Beatriz Moreno (Spain)
12:24	OC1.3	Thyroid hormone replacement therapy for subclinical hypothyroidism in adults: systematic review and meta-analysis of randomized-controlled trials Marieke Snel (Netherlands)
12:36	OC1.4	The Impact of Obligatory Iodine Prophylaxis on Thyroid Volume in Schoolchildren Malgorzata Trofimiuk-Muldner (Poland)
12:48	OC1.5	Low free T3 levels within the reference range independently predict cardiovascular mortality in the general population João Neves (Portugal)
12:00-13:00		Oral Communication: Look who is controlling your gonads! Chair(s):Fasial Ahmed (UK) & Marija Pfeifer (Slovenia) ROOM 113 & 114
12:00	OC2.1	The in vivo and in vitro effects of kisspeptin on human ovarian function Lisa Owens (St James Hospital, Dublin, Ireland)
12:12	OC2.2	Overexpressed kisspeptin/Kiss1R system in human granulosa cells may be involved in the pathogenesis of polycystic ovary syndrome (PCOS) by inhibiting ovulation. Kai-Lun Hu (China)
12:24	OC2.3	Whole exome sequencing in non-obstructive azoospermia allows the identification of a high-risk subgroup of infertile men for undiagnosed Fanconi Anemia, a cancer-prone disease. Csilla Krausz (Italy)
12:36	OC2.4	Novel Role of Central Ceramide Signaling in Mediating Obesity-Induced Precocious Puberty Violeta Heras (Spain)
12:48	OC2.5	Effect of thyroxine replacement on leydig cell and sertoli cell function in men with hypothyroidism Jayakumar Ambigapathy (India)
12:00-13:00		Oral Communication: New insights in bone disorders Chair(s):Claudio Marcocci (Italy) & Barbara Obermayer-Pietsch (Austria) ROOM 117
12:00	OC3.1	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Burosumab, an Anti-FGF23 Antibody, In Adult X-Linked Hypophosphatemia (XLH) Peter Kamenický (France)
12:12	OC3.2	Can a bone protein protect against muscular dystrophy? Jérôme Frenette (Canada)
12:24	OC3.3	[18F]-FDG PET/CT imaging: A tool to reveal the metabolic functions of bone marrow adipose tissue Karla Suchacki (The University of Edinburgh, Edinburgh, UK)
12:36	OC3.4	Renal function change in chronic hypoparathyroidism patients treated with recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and in a historical control cohort treated with standard therapy Kristina Chen (USA)
12:48	OC3.5	Change in bone mineral density during the first 10 years of gender affirming hormonal treatment in transwomen and transmen Chantal Wiepjes (Amsterdam, The Netherlands)
12:00-13:00		Oral Communication: Novel insights into prediabetes and type 2 diabetes Chair(s):Anton Luger (Austria) & Ilhan Satman (Turkey) ROOM 211
12:00	OC4.1	Dietary intervention modulates the expression of the splicing machinery in patients at high-risk of type 2 diabetes development: clinical implications Mercedes Rio-Moreno (Spain)
12:12	OC4.2	Toe brachial index predicts major adverse cardiovascular events in patients with type 2 diabetes Ioana Chisalita (Sweden)
12:24	OC4.3	Effects of TRAIL delivery on an experimental model of type 2 diabetes and diabetic nephropathy Stella Bernardi (Italy)
12:36	OC4.4	Association between prediabetes and incidence of chronic kidney disease, incident albuminuria, or worsening of kidney function: a secondary analysis of the SPRINT trial João Neves (Portugal)
12:48	OC4.5	The impact of prediabetes in lung function: data from the ILERVAS project Enric Sánchez (Spain)
12:00-13:00		UEMS session - Session of the European Union of Medical Specialists Section of Endocrinology Chair(s):Maeve Durkan (Ireland) & Marek Bolanowski (Poland) ROOM 115 & 116
	UEM1.1	News from Brussels Maeve Durkan (Republic of Ireland)
	UEM1.2	ESE/UEMS European Board Examination in Endocrinology, Diabetes and Metabolism Graham Roberts (Republic of Ireland, Waterford, Ireland)
	UEM1.3	UEMS 3E Grant Presentation: Endocrine disruptors and thyroid function during pregnancy Tim Korevaar (Erasmus University Medical Center, Netherlands, Netherlands)
12:00-12:45		Debate 1 - Adrenal venous sampling vs. imaging for primary aldosteronism: beware of the caveats! Chair(s):Laurence Amar (France) & Tomaz Kocjan (Solvenia) AUDITORIUM
	D1.1	For - Adrenal venous sampling vs. imaging for primary aldosteronism: beware of the caveats! Per Hellman (Sweden)
	D1.2	Against - Adrenal venous sampling vs. imaging for primary aldosteronism: beware of the caveats! Jaap Deinum (The Netherlands)
12:00-13:15		Nurses symposium & panel discussion: Bridging the Gap: models of care transitioning endocrine patients for paediatric to adult-oriented care ROOM 111
12:00	N2.1	Key Note Speaker: Principles and models of Transition – an overview Michael Hauschild (Switerland)
12:00-13:15		Nurses symposium & panel discussion: Bridging the Gap: models of care transitioning endocrine patients for paediatric to adult-oriented care
12:30	N2.2	Paediatric to adult transition in Endocrinology Irene Mitchelhill (Australia)
12:35	N2.3	Transition between settings: hospital to community Cristine Yedinak (USA)
12:40	N2.4	Transition in Hypogonadism Sofia Llahana (University of London and University College London Hospitals NHS Foundation Trust, London, UK)
13:00-14:00		Lunch and Poster Viewing EXHIBITION AREA
14:00-14:45		New Scientific Approach 1 - New tools for investigating insulin secretion Chair(s):David Cano (Spain) ROOM 117
	NSA1	New tools for investigating insulin secretion Carsten Schultz (USA)
14:00-14:45		New Scientific Approach 2 - The spliceosome as a target treatment of endocrine tumours Chair(s):Justo Castaño (Spain) ROOM 211
14:00	NSA2	The spliceosome as a target treatment of endocrine tumours Eduardo Eyras (Spain)
14:00-15:00		Satellite symposium
14:00-15:00		Satellite symposium
14:00-15:00		Satellite symposium
15:15-16:00		Debate 2 - Receptor profiling is useful for predicting pituitary therapy Chair(s):Cesar Luiz Boguszewski (Brazil) & Gerald Raverot (France) AUDITORIUM
	D2.1	For - Receptor profiling is useful for predicting pituitary therapy Maria Zatelli (Italy)
	D2.2	Against - Receptor profiling is useful for predicting pituitary therapy Monica Marazulea (Spain)
15:15-16:45		Symposium 6: Precision Medicine for diabetes Chair(s):Manel Puig Domingo (Spain) & Irene Breton (Spain) ROOM 112
15:15	S6.1	Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Jose. Florez (USA)
15:45	S6.2	Can genetics improve precision medicine in diabetes? Leif Groop (Sweden)
16:15	S6.3	Precision nutrition in obesity: gene - diet interaction José Ordovas (USA/Spain)
15:15-16:45		Symposium 7: Expanding the spectrum of thyroid hormone use Chair(s):Josef Köhrle (Germany) & Jose Moreno (Spain) ROOM 211
15:15	S7.1	TRIAC Trial in Allan-Herndon-Dudley-Syndrome (MCT8) Stefan Groeneweg (The Netherlands)
15:45	S7.2	Tetrac as an antiangiogenic agent in cancer Kathrin Schmohl (Germany)
16:15	S7.3	New applications of thyroid hormones, analogs, and metabolites in non-alcoholic fatty liver Paul Yen (Singapore)
15:15-16:45		Symposium 8: Bone fragility – from bench to clinic Chair(s):Camilla Schalin-Jäntti (Finland) ROOM 113 & 114
15:15	S8.1	Clinical spectrum of new monogenic forms of osteoporosis Outi Mäkitie (Helsinki, Finland)
15:45	S8.2	What have we learnt from genome-wide association studies in osteoporosis Fernando Rivadeneira (The Nertherlands)
16:15	S8.3	Hypophosphatasia Lothar Seefried (Germany)
15:15-16:45		Symposium 9: European academy of andrology/ESE Session: Male gonadal function versus general health and vice versa Chair(s):Csilla Krausz (Hungary) & Manuela Simoni (Italy) ROOM 115 & 116
15:15	S9.1	Semen parameters as biomarkers of general health Niels Jørgensen (Juliane Marie centre, Copenhagen, Denmark)
15:45	S9.2	The Klinefelter syndrome: a challenge for endocrinologists Eberhard Nieschlag (University of Münster, Münster, Germany)
16:15	S9.3	Does "healthy obesity" exist in andrology? Giovanni Corona (Italy)
15:15-16:45		Symposium 10: Hot topics in NETs Chair(s):Simona Glasberg (Israel) & Wouter de Herder (Netherlands) ROOM 117
15:15	S10.1	Whole Genome Landscape in pancreatic neuroendocrine tumours
15:45	S10.2	Treatment of small intestine and pancreatic NETs what and when? Marianne Pavel (Germany)
16:15	S10.3	Treatment update on carcinoid syndrome and carcinoid heart disease Staffan Welin (Sweden)
15:15-16:45		European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors Chair(s):Antoine Tabarin (France) & Wiebke Arlt (UK) ROOM 111
15:15	GL1.1	Introduction to ENSAT Guidelines Martin Fassnacht (University Hospital, Würzburg, Germany)
15:20	GL1.2	Methods Olaf Dekkers (Denmark)
15:30	GL1.3	Pathology & Prognostic factors Guillaume Assié (France)
15:45	GL1.4	Adjuvant therapy Massimo Terzolo (Italy)
16:00	GL1.5	Therapy of advanced ACC Martin Fassnacht (University Hospital, Würzburg, Germany)
16:15	GL1.6	Special considerations on mitotane Harm Haak (The Netherlands)
16:45-17:15		Tea & Coffee EXHIBITION AREA
17:15-17:45		Plenary 3 - The wonder world of GnRH neurons - cracking the pulse generator Chair(s):Manel Puig Domingo (Spain) & Bulent Yildiz (Turkey) AUDITORIUM
17:15	PL3	The wonder world of GnRH neurons - cracking the pulse generator Allan Herbison (University of Cambridge, Cambridge, UK)
18:00-19:30		Satellite Symposium
21 May 2018
07:30-18:30		Registration ENTRANCE HALL
08:00-08:45		Meet The Expert 6 - Long term implications of hypoglycaemia in diabetes Chair(s):Judith Lopez (Spain) ROOM 211
	MTE6	Long term implications of hypoglycaemia in diabetes Ilhan Satman (Turkey)
08:00-08:45		Meet The Expert 7 - Difficult cases of differentiated thyroid cancer Chair(s):Gianluca Tamagno (Ireland) AUDITORIUM
	MTE7	Difficult cases of differentiated thyroid cancer Emese Mezosi (Hungary)
08:00-08:45		Meet The Expert 8 - Hormone replacement for the travelling patient Chair(s):Cristina Lamas (Spain) ROOM 112
	MTE8	Hormone replacement for the travelling patient Tina Dusek (Croatia)
08:00-08:45		Meet The Expert 9 - Premature ovarian failure: an endocrine perspective Chair(s):Josanne Vassallo (Malta) ROOM 117
	MTE9	Premature ovarian failure: an endocrine perspective Svetlana Vujovic (Serbia)
08:00-08:45		Meet The Expert 10 - Effects of gender-affirming hormone therapy on bone in transgender persons Chair(s):Mireia Mora (Spain) ROOM 113 & 114
	MTE10	Effects of gender-affirming hormone therapy on bone in transgender persons Guy T'Sjoen (Belgium)
08:00-08:45		Meet the Expert - Basic Scientist 2 -Single-cell sequencing in endocrine diseases Chair(s):Mireia Jorda (Spain) ROOM 115 & 116
	MTEBS2	Single-cell sequencing in endocrine diseases Karine Rizzoti (London, UK)
08:45-09:15		Plenary 4 - The Retina as a Window for Exploring the Brain in Diabetes Chair(s):Susan Webb (Spain) AUDITORIUM
	PL4	The Retina as a Window for Exploring the Brain in Diabetes Rafael Simo (Spain)
09:15-09:45		European Hormone Medal Lecture - Unraveling secrets of the hypothalami-pituitary-gonadal axis Chair(s):Djuro Macut (Serbia) & AJ van der Lely (The Netherlands) AUDITORIUM
	EHM1	Unraveling secrets of the hypothalamic-pituitary-gonadal axis Ilpo Huhtaniemi (Imperial College London , London, UK)
09:45-10:15		Tea & Coffee EXHIBITION AREA
10:15-11:45		Symposium 11: Novel aspects of Craniopharyngioma Chair(s):Cynthia Andoniadou (UK) & Cesar Luiz Boguszewski (Brazil) ROOM 211
10:15	S11.1	Molecular Pathogenensis of Craniopharyngioma Carles Gaston-Massuet (University of London , London, UK)
10:45	S11.2	Bariatric Surgery as Treatment in Craniopharyngioma Daniel Olsson (Sweden)
11:15	S11.3	Psychosocial dysfunction after treatment of of Craniopharyngioma Helen Spoudeas (London))
10:15-11:45		Symposium 12: Why do fractures occur in endocrine disorders and how should they be handled? Chair(s):Massimo Terzolo (Italy) & Nienke Biermasz (The Netherlands) ROOM 117
10:15	S12.1	Increased fracture rate in diabetes and obesity Nicola Napoli (Italy))
10:45	S12.2	Bone quality evaluation in Pituitary diseases Natasha Appelman (The Netherlands)
11:15	S12.3	Effect of parathyroid dysfunction on incidence of bone fractures Jens Bollerslev (Norway)
10:15-11:45		Symposium 13: The colours of fat Chair(s):John Kopchick (USA) & Maria Malagon (Spain) ROOM 113 & 114
10:15	S13.1	Brown adipose tissue as an endocrine organ Francesc Villarroya (Spain)
10:45	S13.2	Adipose Tissue Browning in Mice and Men Florian Kiefer (Austria)
11:15	S13.3	Brown Adipose Tissue Imaging Pirjo Nuutila (Finland)
10:15-11:45		Symposium 14: Neuroendocrine basis of reproductive disorders Chair(s):Manuel Tena-Sempere (Spain) & Allan Herbison (New Zealand) ROOM 115 & 116
10:15	S14.1	Developmental wiring of GnRH neurons Ulrich Boehm (Germany)
10:45	S14.2	Neuroendocrinology right from the nose: genetics and pathophysiology of the olfacto-genital syndrome (Kallmann syndrome) Jean-Pierre Hardelin (France)
11:15	S14.3	Metabolic-reproductive interactions: From bench to bedside Ruben Nogueiras (Spain)
10:15-11:00		Debate 3: Subclinical hypothyroidism is a disease Chair(s):Endre Nagy (Hungary) & Marek Niedziela (Poland) AUDITORIUM
	D3.1	FOR - Subclinical hypothyroidism is a disease Luca Chiovato (Italy)
	D3.2	AGAINST - Subclinical hypothyroidism is a disease Ulla Feldt-Rasmussen (Denmark)
10:15-11:45		Symposium 15: European Young Endocrine Scientists (EYES) New aspects in the study of neuroendocrine diseases Chair(s):Manuel Gahete (Spain) & Tatjana Isailovic (Serbia) ROOM 111
10:15	S15.1	Introduction to EYES Tatjana Isailovic (Serbia)
10:20	S15.2	Metabolic reprogramming of cancer cells Arkaitz Perez (Spain)
10:40	S15.3	Epigenetic and metabolic reprogramming of SDH deficient pheochromocytomas and paragangliomas Judith Favier (France)
11:00	S15.4	Immune Checkpoint Inhibitor Induced Hypophysitis – Experiences from the United Kingdom Punith Kempegowda (University of Birmingham, Birmingham, UK)
11:20	S15.5	Alterations in Clock genes expression in human benign adrenal tumors Anna Angelousi (Greece)
11:40	S15.6	Invitation to EYES networking and annual meeting Manuel Gahete (Spain)
12:00-12:45		Debate 4: AMH as the Primary Marker for Fertility Chair(s):Jenny Visser (Rotterdam) & Stavroula A. Paschou (Greece) ROOM 113 & 114
12:15	D4.1	FOR - AMH as the Primary Marker for Fertility Didier Dewailly (France)
12:15	D4.2	AGAINST - AMH as the Primary Marker for Fertility Joop Laven (The Netherlands)
12:00-13:00		Oral Communication: Diving deep into adrenal cortex diseases Chair(s):Pierre Val (France) & Darko Kaštelan (Croatia) ROOM 117
12:00	OC5.1	Is adrenal computed tomography accurate for the diagnosis of unilateral primary aldosteronism? A retrospective international cohort study Tracy Williams (Germany)
12:12	OC5.2	Steroid profiling by liquid chromatography tandem mass spectrometry in a large cohort of patients with adrenal incidentalomas Guido Dalmazi (Italy)
12:24	OC5.3	PRKACA L206R mutation in adrenal Cushing’s syndrome makes PKA RIIβ susceptible for caspase-mediated cleavage Isabel Weigand (Germany)
12:36	OC5.4	Assessment of Tissue Sodium Content by 23Na-MRI in Patients with Adrenal Insufficiency – a Pilot Study Irina Chifu (Germany)
12:48	OC5.5	Cullin 3 is a partner of Armadillo Repeat Containing 5 (ARMC5), the product of the gene responsible for Primary Bilateral Macronodular Adrenal Hyperplasia Isadora Cavalcante (France)
12:00-13:00		Oral Communication: Genetic and environmental determinants of obesity and insulin resistance Chair(s):Jens Otto Jorgensen (Denmark) & Djuro Macut (Serbia) ROOM 211
12:00	OC6.1	5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo Nikolaos Nikolaou (Oxford, United Kingdom)
12:12	OC6.2	DEEP TRANSCRANIAL MAGNETIC STIMULATION ACUTELY MODULATES NEURO-ENDOCRINE PATHWAYS UNDERLYING OBESITY Anna Ferrulli (Italy)
12:24	OC6.3	Visceral fat assessment in lamin A/C mutation carriers: Phenotype-Genotype correlation Maxime Kwapich (France)
12:36	OC6.4	Anthropometric measurements and metabolic syndrome in relation to glucocorticoid receptor polymorphisms in (local) corticosteroid users Mesut Savas (Netherlands)
12:48	OC6.5	Associations of different body fat deposits with serum 25-hydroxyvitamin D concentrations Rachida Rafiq (Netherlands)
12:00-13:00		Oral Communication: Genomic and clinical aspects of endocrine tumours Chair(s):Attila Patocs (Hungary) AUDITORIUM
12:00	OC7.1	Molecular classification of benign adrenocortical tumors: an integrated genomic study Guillaume Assié (France)
12:12	OC7.2	Urine steroid metabolomics as a diagnostic tool for detection of adrenocortical malignancy – a prospective test validation study Irina Bancos (USA)
12:24	OC7.3	IncRNAs profiling reveals epigenetic heterogeneity among human parathyroid tumor Sabrina Corbetta (Italy)
12:36	OC7.4	Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) gene confer predisposition to metastatic paragangliomas. Alexandre Buffet (France)
12:48	OC7.5	Randomized trial comparing phenoxybenzamine and doxazosine for preoperative treatment of patients with a pheochromocytoma (PRESCRIPT) E Buitenwerf (Netherlands)
12:00-13:00		Oral Communication: MicroRNAs as biomarkers in endocrine diseases Chair(s):Leo Guasti (UK) & Martin Reincke (Germany) ROOM 115 & 116
12:00	OC8.1	Plasma microRNA expression in patients with Cushing’s disease differs from ACTH-ectopic Cushing’s syndrome. Patimat Khandaeva (Russian Federation)
12:12	OC8.2	MicroRNA expression profiling and functional annotation analysis of their targets in patients with diabetic kidney disease. Tais Assmann (Brazil)
12:24	OC8.3	Circulating Levels of microRNAs Associate with Blood Pressure and Left Ventricular Mass in Primary Hypertensive Patients J.C. Kralingen (UK)
12:36	OC8.4	Detecting blood micro-RNAs and proteins associated with Graves’ disease and orbitopathy Filippo Biscarini (Italy)
12:48	OC8.5	MicroRNA profiles in diabetic octogenarians with and without historical and prospective hip fractures Ines Foessl (Austria)
12:00-13:00		Oral Communication: Thyroid from basics to clinics Chair(s):Balasz Gereben (Hungary) & Luca Persani (Italy) ROOM 112
12:00	OC9.1	Increased urinary iodine precedes hypothyroidism in Dehal1 knockout mice Cristian González-Guerrero (Spain)
12:12	OC9.2	Anti-tumoral effects of metformin on metastatic bone lesions of thyroid cancer Sun Cho (Korea, Republic of)
12:24	OC9.3	A mouse model of BRAF V600E mutated papillary thyroid cancer imitating sporadic conditions Iva Jakubíková (Czech Republic)
12:36	OC9.4	Identification of an epigenetic biomarker panel for predicting the development of distant metastases in differentiated thyroid cancer Mireia Jordà (Spain)
12:00-13:00		Meet the Nurse Expert & Case Discussions ROOM 111
12:00	N3.1	Nursing Management of CAH: Education & Use of Multi-media Technology Irene Mitchelhill (Australia)
13:00-14:00		Lunch and Poster Viewing EXHIBITION AREA
13:00-14:00		ESE President meets new members
14:00-15:00		New Scientific Approach 3 - Re-Programming Strategies to Obtain Functional Endocrine Units Chair(s):Karine Rizzoti (UK) ROOM 112
	NSA3	Re-Programming Strategies to Obtain Functional Endocrine Units Leo Guasti (UK)
14:00-15:00		New Scientific Approach 4 - 3D visualisation of the HPG axis in mice and humans Chair(s):Manuel Tena-Sempere (Spain) ROOM 117
	NSA4	3D visualisation of the HPG axis in mice and humans Paolo Giacobini (Milan, Italy)
14:00-15:00		Satellite symposium
14:00-15:00		Satellite symposium
14:00-15:00		Satellite symposium
15:15-16:45		Symposium 16: Changing practice in the management of thyroid neoplasms Chair(s):Marek Ruchala (Poland) & Filip Gablec (Czech Republic) AUDITORIUM
15:15	S16.1	Genomic alterations in thyroid malignancies Garcilaso Riesco-Eizaguirre (Spain)
15:45	S16.2	Composite approach in the evaluation and management of thyroid nodule Murat Erdogan (Turkey)
16:15	S16.3	New classification and guidelines in differentiated thryroid cancers Rossella Elisei (Italy)
15:15-16:45		Symposium 17: Primary Adrenal Macronodular Hyperplasia Chair(s):Gerald Raverot (France) & Javier Salvador (Spain) ROOM 112
15:15	S17.1	Adrenal development and benign tumor formation Pierre Val (France)
15:45	S17.2	Genetics of Primary Adrenal Macronodular Hyperplasia: when and what to test Rossella Libe (France)
16:15	S17.3	Diagnosis and management of Primary Adrenal Macronodular Hyperplasia Dimitra Vassiliadi (Greece)
15:15-16:45		Symposium 18: Borderline testosterone and metabolic outcomes among sexes: clinical relevance Chair(s):Andrea Isidori (Italy) & Gefsi Mintziori (Greece) ROOM 211
15:15	S18.1	Sex hormones, obesity and type 2 diabetes – is there a link? Alessandra Gambineri (Italy)
15:45	S18.2	Relevant therapies in PCOS Mirjana Sumarac-Dumanovic (Serbia)
16:15	S18.3	Testosterone, obesity and the metabolic syndrome in males – do we need to replace steroids? Jean Kaufman (Belgium)
15:15-16:45		Symposium 19: New Aspects of Pituitary Regulation Chair(s):Raúl Luque (Spain) & Federico Gatto (Italy) ROOM 117
15:15	S19.1	Cytoskeleton and pharmacologic resistance in pituitary tumours Giovanna Mantovani (Italy)
15:45	S19.2	What fat does with your pituitary Maria Malagon (Spain)
16:15	S19.3	How cancer treatment effects your pituitary Frederique Albarel (France)
15:15-16:45		Symposium 20: All you need to know about lipodystrophy Chair(s):Gemma Sesmilo (Spain) & Florian Kiefer (Austria) ROOM 113 & 114
15:15	S20.1	Insights in the pathogenesis of lipodystrophy David Savage (University of Cambridge, Cambridge , UK)
15:45	S20.2	Acquired forms of lipodystrophy Giovanni Ceccarini (Italy)
16:15	S20.3	Lipodystrophies, diagnosis and treatment: a step-by-step approach David Vilar (Spain)
15:15-16:15		Publishing Workshop Chair(s):Chair: Beata Kos-Kudła (Poland) Practical publishing advice Room 115 & 116
	PW1.1	Introduction from the Chair Beata Kos-Kudła ()
	PW1.2	Responding to reviewer comments Hans Romijn ()
	PW1.3	How to select your journal and submit your paper Wouter Herder ()
	PW1.4	Publishing ethics Sof Andrikopoulos (Melbourne, Australia)
	PW1.5	Data presentation, precision and ‘pseudoprecision’ Josef Köhrle ()
		Questions and discussion
15:15-17:15		Nurses professional development, networking session and oral/poster presentations Chair(s):Sherwin Cresino (UK) ROOM 111
15:15	N4.1	Welcome and update on ESE nurse activties Sofia Llahana (University of London and University College London Hospitals NHS Foundation Trust, London, UK)
15:30	N4.2	Comparison of glucose, peak growth hormone & peak cortisol levels during insulin tolerance test with two different doses Philip Yeoh (The London Clinic, London, UK)
15:45	N4.3	Role of the Endocrine nurse in the MDT in improving care for patients with thyroid cancer Alina Rozanska (Poland)
16:00	N4.4	Influence of educational training course in improving knowledge of diabetes mellitus among nurses Marcela Xhindi (Albania)
16:45	N4.5	Poster awards presentation, workshops & networking session
16:45-17:15		Tea & Coffee EXHIBITION AREA
17:15-17:45		Clinical Endocrinology Trust Lecture - Growth Hormone: not too much...not too less! Chair(s):Márta Korbonits (UK) & Jens Otto Lunde Jørgensen (Denmark) AUDITORIUM
17:15	CET1	Growth Hormone: not too much...not to less! Philippe Chanson (Paris, France)
17:45-18:15		Plenary 5: The link between insulin and fatty liver Chair(s):Jens Otto Lunde Jørgensen (Denmark) & Márta Korbonits (UK) AUDITORIUM
	PL5	The link between insulin and fatty liver Gerald Shulman (USA)
22 May 2018
08:00-17:00		Registration ENTRANCE HALL
08:00-08:45		Meet The Expert 11 - How to integrate PCSk9 inhibitors into hyperlipademia management Chair(s):Laszlo Bajnok (Hungary) ROOM 113
	MTE11	How to integrate PCSk9 inhibitors into hyperlipademia management Carmen Georgescu (Romania)
08:00-08:45		Meet The Expert 12 - Controversies in NETs: Is high dose SSA treatment relevant and who needs hemicolectomy? Chair(s):Diego Ferone (UK) ROOM 115 & 116
	MTE12	Controversies in NETs: Is high dose SSA treatment relevant and who needs hemicolectomy? Gregory Kaltsas (Greece)
08:00-08:45		Meet The Expert 13 - Erectile Dysfunction Chair(s):Csilla Krausz (Italy) AUDITORIUM
	MTE13	Erectile Dysfunction Mario Maggi (Italy)
08:00-08:45		Meet The Expert 14 - Vitamin D for everybody Chair(s):Peter Igaz (Hungary) ROOM 114
	MTE14	Vitamin D for everybody? Stefan Pilz (Austria)
08:00-08:45		Meet The Expert 15 - Your emergency consult about hyponatraemia Chair(s):Isabelle Runkle de la Vega (Spain) ROOM 117
	MTE15	Your emergency consult about hyponatraemia Nigel Glynn (UK)
08:00-08:45		Meet The Expert 16 - Adrenal incidentaloms Chair(s):Duarte Pignatelli (Portugal) ROOM 112
	MTE16	Adrenal incidentaloms John Newell-Price (University of Sheffield, Sheffield, UK)
08:00-08:45		Meet The Expert - Basic Scientist 3: Watch out for noncanonical mechanisms of thyroid hormone action! Chair(s):Pilar Santisteban (Spain) ROOM 111
	MTBS3	Watch out for noncanonical mechanisms of thyroid hormone action! Lars Moeller (Essen, Germany)
08:45-09:15		Plenary 6: Does therapy for thyroid dysfunction decrease mortality? Chair(s):Beata Kos-Kudła (Poland) & Endre Nagy (Hungary) AUDITORIUM
	PL6	Does therapy for thyroid dysfunction decrease mortality? Laszlo Hegedus (Denmark)
09:15-09:45		Tea & Coffee EXHIBITION AREA
09:45-11:15		Symposium 21: The Dance of Adrenal and Gonads Chair(s):Andrea Isidori (Rome) & Ljiljana Marina (Serbia) AUDITORIUM
09:45	S21.1	The interplay Between the Ovaries and Adrenals Duarte Pignatelli (Portugal)
10:15	S21.2	Management of phaeochromocytoma during pregnancy Scott Akker (London, UK)
10:45	S21.3	Fertility in Congenital Adrenal Hyperplasia Blazej Meczekalski (Poland)
09:45-11:15		Symposium 22: The fatty bone Chair(s):Eugenia Resmini (Spain) & Luís Cardoso (Portugal) ROOM 112
09:45	S22.1	Marrow adipose tissue and skeletal health Tim Schulz (Germany)
10:15	S22.2	Bone marrow adipose tissue: starving for attention? William Cawthorn (Centre for Cardiovascular Science, University of Edinburgh, Edinburgh , Scotland)
10:45	S22.3	Cross-talk between bone marrow and periperal adipose tissue in man Peter Arner (Sweden)
09:45-11:15		Symposium 23: Pre-diabetes Chair(s):Alejandra Duran (Spain) & Peter Aldiss (UK) ROOM 115 & 116
09:45	S23.1	What have we learnt so far about the immunogenetics of type 1 diabetes? John Todd (UK)
10:15	S23.2	Prevention and treatment of pre type 1 diabetes Anette Ziegler (Germany)
10:45	S23.3	Treatment of pre type 2 diabetes Riccardo Bonadonna (Itay)
09:45-11:15		Symposium 24: Ups and downs of hypothalamo-pituitary hormones Chair(s):Cynthia Andoniadou (UK) ROOM 113
09:45	S24.1	How Does Pituitary Release its Hormones? Patrice Mollard (Montpellier, France)
10:15	S24.2	Peripheral Activities of Growth Hormone-Releasing Hormone (GHRH) Riccarda Granata (Italy)
10:45	S24.3	How Do Hypopituitary Patients Deal with Stress? Niels Moeller (Denmark)
09:45-11:15		Symposium 25: Late breaking Chair(s):Márta Korbonits (UK) & Raúl Luque (Spain) ROOM 114
09:45	S25.1	Microvesicles and exosomes: new players in metabolic diseases Francesc Borras (Spain))
10:15	S25.2	Senescence-associated reprogramming promotes cancer stemness Clemens Schmitt (Germany)
10:45	S25.3	LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor Daniel Kaplan (USA)
09:45-10:30		Debate 5: Pregnant women should be screened for thyroid hormones and antibodies Chair(s):Andrzej Milewicz (Poland) & Wilmar Wiersinga (The Netherlands) ROOM 117
	D5.1	FOR - Pregnant women should be screened for thyroid hormones and antibodies Kristien Boelaert (University of Birmingham, Birmingham, UK)
	D5.2	AGAINST - Pregnant women should be screened for thyroid hormones and antibodies Brigitte Velkeniers (Brussels)
09:45-10:45		Endo-ERN: concrete examples of added value for patient care Chair(s):Jérôme Bertherat (France) & Thierry Brue (France) ROOM 111
09:45		Introduction, structure, and virtual consultation using the EU-ERN CPMS Alberto Pereira (Amsterdam, The Netherlands)
10:00		Caring for endocrinology across the life span: DSD and Hypogonadotropic hypogonadism Olaf Hiort (Lübeck, Germany)
10:15		Patient and family perspectives Mrs Manuela Brösamle (Germany)
11:30-12:15		Debate 6: Endocrine disruptors: Regulatory vs. Scientific Perspectives Chair(s):Helen Spoudeas (UK) & Jorma Toppari Turku (Finland) ROOM 114
	D6.1	SCIENCE - Endocrine disruptors: Regulatory vs. Scientific Perspectives Nicolás Olea (Spain)
	D6.2	REGULATORY - Endocrine disruptors: Regulatory vs. Scientific Perspectives Sharon Munn ()
11:30-12:30		Oral Communication: Cardiovascular aspects of endocrine diseases Chair(s):Miklos Toth (Hungary) & Davide Carvalho (Portugal) AUDITORIUM
11:30	OC10.1	Glucocorticoid replacement-doses and cardiovascular events in autoimmune Addison’s disease – a population based retrospective cohort study. Jakob Skov (Sweden)
11:42	OC10.2	Canagliflozin attenuates the progression of atherosclerosis via reducing hyperlipidaemia and inflammation process in ApoE KO Mice Narjes Nasiri-Ansari (Greece)
11:54	OC10.3	ARMC5 variants and risk of hypertension in African Americans: Minority Health-GRID study Mihail Zilbermint (USA)
12:06	OC10.4	Improvement in the control of hypertension in diabetic patients screened for hyperaldosteronism Inés Jimenez (Spain)
12:18	OC10.5	Increased Risk of Antithyroid Drug-induced Agranulocytosis with Amiodarone Michal Gershinsky (Israel)
11:30-12:30		Oral Communication: Clinical practice in endocrine tumours: combining conventional and molecular features Chair(s):Justo Castaño (Spain) & Irene Halperin (Spain) ROOM 117
11:30	OC11.1	Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication. Cristina Ronchi (University of Birmingham, Birmingham, United Kingdom)
11:42	OC11.2	Molecular classifiers refine the prognostic stratification of adrenocortical carcinoma Anne Jouinot (France)
11:54	OC11.3	Clinical and histopathological differences between MEN1 carriers and MEN1 phenocopy patients Tatjana Isailovic (Serbia)
12:06	OC11.4	Update in the genetic landscape of Cushing’s Disease: TP53 and a new deubiquitinase in spotlight Silviu Sbiera (Germany)
12:18	OC11.5	Natural history of Rathke’s Cleft Cysts: a multicenter experience Elisa Sala (Italy)
11:30-12:30		Oral Communication: Novel aspects of puberty development and Cushing's disease Chair(s):Susan Webb (Spain) & Jean-Marc Kaufman (Belgium) ROOM 115 & 116
11:30	OC12.1	Growth hormone signaling in leptin receptor expressing cells, but not in Kiss1 expressing neurons, regulates the timing of puberty Renata Frazao (Brazil)
11:42	OC12.2	Oligogenicity in Kallmann syndrome - an underestimated phenomenon? Małgorzata Kałużna (Poland)
11:54	OC12.3	Evaluation of genetic predisposition in severe and mild phenotypes of isolated hypogonadotropic hypogonadism Biagio Cangiano (Italy)
12:06	OC12.4	Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing’s disease (CD) Andre Lacroix (UK)
12:18	OC12.5	Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN. Elena Valassi (Spain)
11:30-12:30		Oral Communication: The curious case of growth hormone Chair(s):Sebastian Neggers (The Netherlands) & Susana Mallea-Gil (Argentina) ROOM 113
11:30	OC13.1	Postoperative use of somatostatin analogs and mortality in patients with acromegaly. Mark Postma (Netherlands)
11:42	OC13.2	Time trends of mortality in patients with GH secreting and non-functioning pituitary adenoma. Simona Galoiu (Romania)
11:54	OC13.3	Molecular profiling for assistance to pharmacological treatment of acromegaly Manuel Puig-Domingo (Spain)
12:06	OC13.4	Effects of Pegvisomant on Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies Tiziana Feola (Italy)
12:18	OC13.5	Growth hormone acts in AGRP neurons to control energy expenditure during food restriction and promotes counter-regulatory responses to hypoglycemia via the ventromedial hypothalamus Isadora Furigo (Brazil)
11:30-12:30		Oral Communication: What is new in gestational and type 1 diabetes? Chair(s):Carlo Acerini (UK) ROOM 112
11:42	OC14.2	Profiling of activation patterns of placental mTOR in pregnancies complicated by gestational diabetes mellitus Anna Papadopoulou (Greece)
11:54	OC14.3	Patrolling monocytes are activated in diabetes and provide protection to retinal vessels in the context of leukostasis. Francesco Tecilazich (USA)
12:06	OC14.4	The variability of glycemia and the metabolic composition of brain cells in patients with type 1 diabetes mellitus Maria Rotkank (Russian Federation)
12:18	OC14.5	Type 1 diabetes mellitus: defining the best cut-off points of arterial stiffness for predicting cardiovascular risk according to the Steno Type 1 Risk Engine Albert Cano (Spain)
11:30-12:30		ESE Council of Affiliated Societies Session Room 111
12:30-13:30		Lunch and Poster Viewing Chair(s):Please note the exhibition will close to delegates at 14:30 hrs EXHIBITION AREA
12:45-13:30		ESE Annual General Meeting All ESE members are welcome to attend Room 111
13:30-14:15		New Scientific Approach 5 - Circulating miRNAs in Endocrine Tumours Chair(s):Giovanna Mantovani (Italy) ROOM 112
	NSA5	Circulating miRNAs in Endocrine Tumours Peter Igaz (Hungary)
13:30-14:15		New Scientific Approach 6 - Functional thyroid in the dish Chair(s):Robin Peeters (The Netherlands) ROOM 115 & 116
	NSA6	Functional thyroid in the dish Sabine Costagliola (Université de Genève, Brussels, Belgium)
14:45-16:15		Symposium 26: Cortisol: Too much of a Good Thing Chair(s):Darko Kaštelan (Croatia) & Andrea Isidori (Rome) AUDITORIUM
14:45	S26.1	Genetics of Cushing's disease Laura Ramírez (USA)
15:15	S26.2	Hypercortisolism and the Brain Nicolaas Wee (The Netherlands)
15:45	S26.3	Differentiating Cushing from Pseudo-Cushing Krystallenia Alexandraki (Greece)
14:45-16:15		Symposium 27: Emerging treatments in osteoporosis Chair(s):Mariela Varsavsky (Argentina) & Mário Mascarenhas (Portugal) ROOM 112
14:45	S27.1	Molecular basis of bone anabolism Thomas Clemens (USA)
15:15	S27.2	Novel therapies: PTH-related protein and sclerostin inhibition Tilman Rachner (Germany)
15:45	S27.3	Sequential and combination therapy for osteoporosis Zhanna Belaya (Russia)
14:45-16:15		Symposium 28: Endocrinology Meets Immunology Chair(s):Justo Castaño (Spain) & Miklós Tóth (Hungary) ROOM 117
14:45	S28.1	Concept of Immunotherapy in Cancer Michal Lotem (Israel)
15:15	S28.2	Immunotherapy for Thyroid Carcinoma Efisio Puxeddu (Italy)
15:45	S28.3	Immunotherapy Related Endocrinopathies Mark Vanderpump (London)
14:45-16:15		Symposium 29: Thyroid hormone action: regulation and clinical implications Chair(s):Dusan Biukovic (Bosnia and Herzegovina) & Murat Erdogen (Turkey) ROOM 115 & 116
14:45	S29.1	Tissue-specific regulation of thyroid hormone action Balázs Gereben (Hungary)
15:15	S29.2	Thyroid hormone economy in human aging Diana Heemst (Leiden, The Netherlands)
15:45	S29.3	Elevated TSH in Children Annette Grüters-Kieslich (Charité University Medicine , Berlin, Germany)
14:45-16:15		Symposium 30: Disorders of Sexual Development (DSD) Chair(s):Laura Audi (Spain) & Laura de Graaff (The Netherlands) ROOM 113
14:45	S30.1	Long term consequences of Disorders of Sexual Development Lina Michala (Greece)
15:15	S30.2	Atypical Genital Development and Hypospadias: a Pediatric Urology perspective from Etiology to Surgery Nicolas Kalfa (France)
15:45	S30.3	Gender Dysphoria and Brain Function Julie Bakker (Belgium)
14:45-16:15		Career Development - Presentation Skills Workshop Chair(s):Roy Sheppard (UK) Roy is a professional speaker who will share priceless and unexpected tips and techniques that the professionals use so that you can transform your presentations
16:15-16:45		Tea & Coffee ENTRANCE HALL
16:45-17:15		ESE Awards Presentation AUDITORIUM
17:15-17:45		Plenary 7: Metabolic control of longevity Chair(s):Raúl Luque (Spain) & Felix Beuschlein (Germany) AUDITORIUM
17:15	PL7	Metabolic control of longevity Manuel Serrano (Spain)
17:45-18:00		Closing Ceremony AUDITORIUM

ECE2018

19 May 2018

20 May 2018

21 May 2018

22 May 2018